Petros Pharmaceuticals, Inc.
PTPI evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $254K
- Lead Asset:
- stendra (Approved)
What it means
What to watch
Prepared research question
What matters most for PTPI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTPI
Petros Pharmaceuticals, Inc. (PTPI) is a company focused on expanding consumer access to medication through over-the-counter drug development programs, with a pipeline anchored by the approved erectile dysfunction drug avanafil (Stendra).
Key risk: Low equity cushion
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Petros Pharmaceuticals, Inc..
Petros Pharmaceuticals, Inc. (PTPI) is a company focused on expanding consumer access to medication through over-the-counter drug development programs, with a pipeline anchored by the approved erectile dysfunction drug avanafil (Stendra).
- Petros Pharmaceuticals is focused on expanding consumer access to medication through over-the-counter (OTC) drug development programs [news · published 2025-06-25].
- The company's pipeline includes Stendra (avanafil), an approved PDE-5 inhibitor for erectile dysfunction, licensed from Vivus, Inc. for rights in the U.S., Canada, South America, and India [pipeline].
- As of 2026-06-30, Petros reported cash & equivalents of $3.5M, net income of -$1.0M, and shareholders' equity of $0.7M [sec].
- In May 2025, Petros reported having more than $10M in cash and a significantly reduced burn rate, positioning it to fully fund development of its technology platform [news · published 2025-05-20].
- In June 2025, Petros announced the deconsolidation of its Metuchen Pharmaceuticals subsidiary to strengthen its balance sheet and improve equity position [news · published 2025-06-25].
What works
- Petros has an approved product (avanafil/Stendra) in a large market (erectile dysfunction), providing a commercial asset and potential revenue stream [pipeline].
- The company reported a significantly reduced burn rate and over $10M in cash as of May 2025, suggesting improved financial discipline [news · published 2025-05-20].
- The deconsolidation of Metuchen Pharmaceuticals in June 2025 was intended to strengthen the balance sheet and improve equity position [news · published 2025-06-25].
What to weigh
- The company reported a net loss of -$1.0M for the period ending 2026-06-30, indicating ongoing unprofitability [sec].
- Shareholders' equity was only $0.7M as of 2026-06-30, reflecting a thin equity cushion [sec].
- The erectile dysfunction market is highly competitive, with generic sildenafil and tadalafil, as well as multiple competitor trials from companies like Bayer, Eli Lilly, and Vigonvita Life Sciences [pipeline][competitor_trial].
From the filings
Quoted directly from source documents.
Petros focuses on OTC drug development programs
“a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs”
News · June 25, 2025
Petros licensed avanafil rights from Vivus
“Petros licensed rights to develop, market, sell, and distribute avanafil in the United States, Canada, South America, and India.”
Cash position and burn rate as of May 2025
“With more than $10m in cash, and a significantly reduced burn rate, the Company is positioned to fully fund the development of its technology platform.”
News · May 20, 2025
Deconsolidation of Metuchen Pharmaceuticals
“Petros Pharmaceuticals Announces Deconsolidation of Metuchen Pharmaceuticals Subsidiary, Strengthening its Balance Sheet and Improving the Company's Equity Position”
News · June 25, 2025
Risks & what to watch (3)›
Key risks
- Low equity cushion — Shareholders' equity of $0.7M as of 2026-06-30 provides a thin buffer against losses [sec].
- Ongoing net losses — Net loss of -$1.0M for the period ending 2026-06-30 indicates continued unprofitability [sec].
- Intense ED market competition — Generic sildenafil and tadalafil, plus multiple competitor trials from Bayer, Eli Lilly, and others, pressure avanafil's market share [pipeline][competitor_trial].
What to watch
- Progress of Petros' OTC drug development programs and any regulatory milestones [news · published 2025-06-25].
- Financial performance, particularly whether the reduced burn rate and cash position lead to improved net income in future quarters [news · published 2025-05-20][sec].
- Impact of the Metuchen Pharmaceuticals deconsolidation on the company's balance sheet and equity position [news · published 2025-06-25].
- Competitive developments in the erectile dysfunction market, including trials from Bayer, Eli Lilly, and Vigonvita Life Sciences [competitor_trial].
Sources: Competitor trials · News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Petros Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Petros Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 4.06 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of May 22, 2026- % of float
- 25.1%
- Days to cover
- 0.2
- Shares short
- 493,829
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PTPI short interestGovernance
Frequently asked questions
What is the AI investment thesis for Petros Pharmaceuticals, Inc.?
Petros Pharmaceuticals, Inc. (PTPI) is a company focused on expanding consumer access to medication through over-the-counter drug development programs, with a pipeline anchored by the approved erectile dysfunction drug avanafil (Stendra).
What is Petros Pharmaceuticals, Inc.'s lead drug candidate?
Petros Pharmaceuticals, Inc.'s most advanced tracked candidate is stendra (Approved) for Erectile dysfunction (ED).
Who is the CEO of Petros Pharmaceuticals, Inc.?
Exchange Act is the chief executive officer of Petros Pharmaceuticals, Inc. (PTPI).
Where is Petros Pharmaceuticals, Inc. headquartered?
Petros Pharmaceuticals, Inc. (PTPI) is headquartered in New York, NY, United States.
What therapeutic areas does Petros Pharmaceuticals, Inc. focus on?
Petros Pharmaceuticals, Inc. develops therapies across Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.